NTF3 and myeloid sarcoma: We identified in this meta-analysis 16 potential therapies to improve remyelination in MS patients that have not yet been tested in clinical trials: Apotransferrin, Benztropine, Epimedium flavonoids, Estrogen receptor agonist G1, Iloprost, Indazol chloride, N6-cyclohexyladenosine, Neurotrophin 3, Ninjin’yoeito, Olesoxime, PEDF, PDGF, Sildenafil, siRNA against Nogo-receptor, Sonic hedgehog, and Tocopherol derivate TFA-12.